Latest news

Tubulis’ ADC shows 59% response rate, fueling investor and clinical momentum

Tubulis’ ADC shows 59% response rate, fueling investor and clinical momentum

Joachim Eeckhout
Daily Snap - 20. October 2025

Daily Snap - 20. October 2025

Joachim Eeckhout
Roche breast cancer pill slashes progression risk by 62% in key trial

Roche breast cancer pill slashes progression risk by 62% in key trial

Joachim Eeckhout
Evaxion’s cancer vaccine shows 75% response but funding shortfall limits trial impact

Evaxion’s cancer vaccine shows 75% response but funding shortfall limits trial impact

Joachim Eeckhout
Daily Snap - 17. October 2025

Daily Snap - 17. October 2025

Joachim Eeckhout
Adcytherix raises €105M to supercharge next-gen cancer therapies

Adcytherix raises €105M to supercharge next-gen cancer therapies

Joachim Eeckhout
Praxis’ tremor drug triumph sends stock soaring 200%+

Praxis’ tremor drug triumph sends stock soaring 200%+

Joachim Eeckhout
Daily Snap - 16. October 2025

Daily Snap - 16. October 2025

Joachim Eeckhout
Hair-loss startup Pelage lands $120M to advance breakthrough regenerative gel

Hair-loss startup Pelage lands $120M to advance breakthrough regenerative gel

Eduardo Longoria
Tubulis lands €308 million in record Series C to lead next-gen cancer drug race

Tubulis lands €308 million in record Series C to lead next-gen cancer drug race

Eduardo Longoria
Daily Snap - 15. October 2025

Daily Snap - 15. October 2025

Joachim Eeckhout
Kailera raises $600M to take on Eli Lilly in obesity drug race

Kailera raises $600M to take on Eli Lilly in obesity drug race

Eduardo Longoria
FirstBack
7891011121314
Next Last